Rimegepant sulfate ODT is under clinical development by Pfizer and currently in Phase III for Rhinosinusitis. According to GlobalData, Phase III drugs for Rhinosinusitis have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rimegepant sulfate ODT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rimegepant sulfate ODT overview

Rimegepant sulfate (Nurtec, Vydura) is an anti-migraine agent. It is formulated as disintegrating tablets and lyophilized tablets for oral route of administration. It is indicated for the acute treatment of migraine with or without aura in adults and also indicated for the preventive treatment of episodic migraine in adults and chronic rhinosinusitis with or without nasal polyps.

Rimegepant is under development for psoriasis, cluster headache, chronic rhinosinusitis, huntington disease, acute treatment and prevention of migraine in China. The drug candidate is administered as orally dissolving tablet. It is a new chemical entity which acts by targeting calcitonin gene related peptide (CGRP) receptor.

It was under development for the treatment of refractory trigeminal neuralgia,  temporomandibular disorder (TMD).

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of Rimegepant sulfate ODT’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.